Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This source reports that the approval of baricitinib and ritlecitinib, which are JAK inhibitors, has marked a significant advancement in treating severe alopecia areata (AA), and suggests that additional treatments with new mechanisms may further improve patient outcomes in the future.

This announcement discusses the recent FDA approval of baricitinib for treating severe alopecia areata in adults and reports no new clinical results.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

This study found that Janus Kinase inhibitors, tofacitinib and baricitinib, showed effectiveness and safety in treating severe alopecia areata in a real-world setting, with optimal tolerability noted in younger individuals.

This report documents the first known case of acute inflammatory demyelinating polyneuropathy potentially linked to pegylated interferon-alpha 2a in a woman undergoing treatment for chronic hepatitis C.

In this study, the authors highlight the potential of intradermal microinjections of dutasteride as an adjunctive therapy for androgenetic alopecia, though they note that information on its effectiveness remains limited.

In this case report, a 24-year-old woman with Down syndrome effectively managed coexisting alopecia areata and hidradenitis suppurativa using upadacitinib, following partial success with previous treatments.

Baricitinib stops hair loss and promotes regrowth in alopecia areata.

This study highlights the recent FDA approval of baricitinib as the first on-label treatment for severe alopecia areata, whereas previous treatments were off-label therapies like systemic steroids and immunosuppressants.

This case report describes a patient who developed severe alopecia and a rash after increasing captopril dosage, which resolved upon discontinuing the medication.

In this study, JAK inhibitors significantly improved outcomes for patients with both atopic dermatitis and alopecia areata, while dupilumab was linked to worsening alopecia in some cases.

This study developed and tested continuous implanters for dermal papilla cell aggregates, finding that the bar-cartridge type implanter is the most effective design for continuous cell implantation in androgenetic alopecia research.

This study aimed to evaluate the outcomes of switching between two JAK inhibitors, tofacitinib and baricitinib, in treating alopecia areata, due to the lack of data on their comparative efficacy.

This case report found that a 48-year-old woman with idiopathic twenty-nail dystrophy experienced significant improvement in nail appearance after six months of treatment with oral Upadacitinib.

In a mouse study, JAK inhibitors like Jakafi and Xeljanz prevented alopecia areata and aided hair regrowth; similar effects were observed in three patients with the condition.

This 104-week follow-up trial found that baricitinib is effective and safe for treating severe alopecia areata but requires continuous use to sustain hair regrowth. The drug is included in the NVDV guidelines and reimbursed by Dutch insurers for this purpose.

This study observed that in live rodents, actin filaments adjust their structure to facilitate membrane transfer between cellular compartments; linear filaments stabilize fused membranes, while branched filaments, connected by the protein Ezrin, drive integration, demonstrating actin's role in adapting to membrane biophysical changes.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

This review examines clinical data on the efficacy and safety of JAK inhibitors used for immune-mediated conditions beyond rheumatoid arthritis, highlighting their potential therapeutic roles in various inflammatory diseases.

This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.

This study found that targeting the p300/androgen receptor axis effectively reduced AR activation and ovarian fibrosis in mouse models of polycystic ovary syndrome, suggesting a potential therapeutic approach.

This article discusses baricitinib, a JAK1 and JAK2 inhibitor, as an approved and promising treatment for alopecia areata but reports no new clinical results.

This case study reports that a man with severe patch-type alopecia areata initially responded to baricitinib treatment but experienced a relapse despite ongoing therapy.

In this report, a 58-year-old woman with ocular myasthenia gravis experienced complete resolution of symptoms and hair regrowth after six months of treatment with the JAK inhibitor baricitinib, highlighting a potential new therapeutic approach for this condition.

This study found that the proprietary aptamer TAGX-0003 significantly inhibited IFNγ-induced effects in pre-clinical human models of alopecia areata, promoting hair regrowth and potentially preventing disease relapse.

This report presents a case of a patient developing new multiple sclerosis while using tofacitinib for alopecia areata, noting no new comprehensive research findings.

This review discusses auxin's role in regulating plant growth through TOR activation and translation reinitiation but reports no new experimental findings.

This study observed that topically applied RTA 408 reduced the severity of radiation-induced dermatitis in mice, with the highest dose significantly reducing and alleviating skin damage and associated inflammation.

The 308-nm excimer laser helps hair regrowth in some alopecia areata cases but not all.

In this report, a female patient with ulcerative colitis, alopecia areata, and pyoderma gangrenosum showed improvement in all three conditions after being treated with tofacitinib.